BioCentury | Jun 26, 2019
Product Development

AbbVie chooses revenue over innovation with Allergan takeout

Six years after splitting from Abbott to pursue innovative drug development, AbbVie has taken a clear about-face, choosing a certain immediate revenue stream in its proposed acquisition of Allergan rather than opting for a riskier,...
BC Week In Review | Jan 18, 2019
Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late on Jan. 16. The price is a slim discount to the...
BC Extra | Jan 17, 2019
Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late Wednesday. The price is a slim discount to the company’s close...
BC Week In Review | Jan 12, 2018
Clinical News

Revance's RT002 misses in Phase IIa for plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) said DaxibotulinumtoxinA for Injection (RT002) missed the primary endpoint of reducing patient-reported foot pain as measured by visual analog scale (VAS) score from baseline to week eight vs. placebo in a...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Dec 8, 2017
Clinical News

Revance's RT002 meets in pair of Phase III trials for frown lines

Revance Therapeutics Inc. (NASDAQ:RVNC) said a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and SAKURA 2 trials to treat moderate to severe...
BC Week In Review | Dec 8, 2017
Financial News

Revance raises $150M in follow-on

Revance Therapeutics Inc. (NASDAQ:RVNC) raised $150 million on Dec. 7 through the sale of 4.8 million shares at $31 in a follow-on underwritten by Goldman Sachs, Cowen, Barclays, Cantor Fitzgerald, William Blair and SunTrust Robinson...
BC Extra | Dec 7, 2017
Financial News

Revance raises $150M in follow-on

Revance Therapeutics Inc. (NASDAQ:RVNC) raised $150 million on Thursday through the sale of 4.8 million shares at $31 in a follow-on underwritten by Goldman Sachs, Cowen, Barclays, Cantor Fitzgerald, William Blair and SunTrust Robinson Humphrey....
BC Extra | Dec 5, 2017
Clinical News

Phase III frown lines data boost Revance shares

Revance Therapeutics Inc. (NASDAQ:RVNC) rose $8.75 (34%) to $34.75 Tuesday after reporting that a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and...
BC Week In Review | Nov 3, 2017
Clinical News

Revance completes enrollment in Phase II trial of RT002 to treat plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) completed enrollment of 59 patients in a Phase II trial of daxibotulinumtoxinA for injection (RT002) to treat plantar fasciitis. The double-blind, placebo-controlled, U.S. trial is evaluating single injections of 240 units...
Items per page:
1 - 10 of 27